Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines

NCT05496335 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05496335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05496335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
August 30, 2022
Completion date
May 30, 2023
Enrollment
90 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines